Cargando…
The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
OBJECTIVE: This study introduces innovative strategies, the doublet regimen of concurrent chemoradiotherapy, to ensure longer survival for locoregionally advanced nasopharyngeal carcinoma. METHODS: We retrospectively reviewed 104 locoregionally advanced nasopharyngeal carcinoma patients who underwen...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673321/ https://www.ncbi.nlm.nih.gov/pubmed/36397078 http://dx.doi.org/10.1186/s13014-022-02158-4 |
_version_ | 1784832919880073216 |
---|---|
author | Wang, Zhi-Qiang Feng, Xu-Dong Ge, Chun-Lei Yang, Yi Liang, Na Ye, Qing Fu, Yang Wei, Jian Zhang, Yong Li, Rong-Qing |
author_facet | Wang, Zhi-Qiang Feng, Xu-Dong Ge, Chun-Lei Yang, Yi Liang, Na Ye, Qing Fu, Yang Wei, Jian Zhang, Yong Li, Rong-Qing |
author_sort | Wang, Zhi-Qiang |
collection | PubMed |
description | OBJECTIVE: This study introduces innovative strategies, the doublet regimen of concurrent chemoradiotherapy, to ensure longer survival for locoregionally advanced nasopharyngeal carcinoma. METHODS: We retrospectively reviewed 104 locoregionally advanced nasopharyngeal carcinoma patients who underwent taxane combined platinum-based concurrent chemoradiotherapy in our center between January 2013 and December 2018. All statistical analyses were performed using the Kaplan–Meier method (SPSS 23.0). Different groups were compared with the Wilcoxon rank-sum test. RESULTS: Ultimately, 104 patients were selected for this study, including 18 and 86 who received either concurrent chemoradiation therapy alone or concurrent chemoradiation therapy plus adjuvant chemotherapy, respectively. The median follow-up time for progression free survival was 53.0 months (IQR 48.5–57.5). The 3-years progression-free survival (PFS), overall survival (OS), local–regional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) rates of the doublet regimen of concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma were 85.9%, 96.0%, 96.0% and 90.8%, respectively. Additionally, we analyzed the subgroups and found that the 3-years PFS, OS, LRRFS and DMFS rates for stage III versus stage IVa were 97.8% versus 75.5% (P = 0.000), 100% versus 92.5% (P = 0.004), 100% versus 92.4% (P = 0.015) and 97.8% versus 82.8% (P = 0.002), respectively. During concurrent chemotherapy, acute chemotherapy adverse events of grade 3 or 4 was only 18.3%. Leukopenia was the most common acute chemotherapy adverse event (in 10 patients [9.6%]), followed by neutropenia (in 8 patients [7.6%]). CONCLUSION: The doublet regimen of taxane plus platinum concurrent chemoradiotherapy resulted in improved long-term survival of locoregionally advanced nasopharyngeal carcinoma patients, especially for local control rate and warrants further prospective evaluation. |
format | Online Article Text |
id | pubmed-9673321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96733212022-11-19 The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study Wang, Zhi-Qiang Feng, Xu-Dong Ge, Chun-Lei Yang, Yi Liang, Na Ye, Qing Fu, Yang Wei, Jian Zhang, Yong Li, Rong-Qing Radiat Oncol Research OBJECTIVE: This study introduces innovative strategies, the doublet regimen of concurrent chemoradiotherapy, to ensure longer survival for locoregionally advanced nasopharyngeal carcinoma. METHODS: We retrospectively reviewed 104 locoregionally advanced nasopharyngeal carcinoma patients who underwent taxane combined platinum-based concurrent chemoradiotherapy in our center between January 2013 and December 2018. All statistical analyses were performed using the Kaplan–Meier method (SPSS 23.0). Different groups were compared with the Wilcoxon rank-sum test. RESULTS: Ultimately, 104 patients were selected for this study, including 18 and 86 who received either concurrent chemoradiation therapy alone or concurrent chemoradiation therapy plus adjuvant chemotherapy, respectively. The median follow-up time for progression free survival was 53.0 months (IQR 48.5–57.5). The 3-years progression-free survival (PFS), overall survival (OS), local–regional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) rates of the doublet regimen of concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma were 85.9%, 96.0%, 96.0% and 90.8%, respectively. Additionally, we analyzed the subgroups and found that the 3-years PFS, OS, LRRFS and DMFS rates for stage III versus stage IVa were 97.8% versus 75.5% (P = 0.000), 100% versus 92.5% (P = 0.004), 100% versus 92.4% (P = 0.015) and 97.8% versus 82.8% (P = 0.002), respectively. During concurrent chemotherapy, acute chemotherapy adverse events of grade 3 or 4 was only 18.3%. Leukopenia was the most common acute chemotherapy adverse event (in 10 patients [9.6%]), followed by neutropenia (in 8 patients [7.6%]). CONCLUSION: The doublet regimen of taxane plus platinum concurrent chemoradiotherapy resulted in improved long-term survival of locoregionally advanced nasopharyngeal carcinoma patients, especially for local control rate and warrants further prospective evaluation. BioMed Central 2022-11-17 /pmc/articles/PMC9673321/ /pubmed/36397078 http://dx.doi.org/10.1186/s13014-022-02158-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wang, Zhi-Qiang Feng, Xu-Dong Ge, Chun-Lei Yang, Yi Liang, Na Ye, Qing Fu, Yang Wei, Jian Zhang, Yong Li, Rong-Qing The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study |
title | The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study |
title_full | The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study |
title_fullStr | The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study |
title_full_unstemmed | The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study |
title_short | The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study |
title_sort | long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673321/ https://www.ncbi.nlm.nih.gov/pubmed/36397078 http://dx.doi.org/10.1186/s13014-022-02158-4 |
work_keys_str_mv | AT wangzhiqiang thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT fengxudong thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT gechunlei thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT yangyi thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT liangna thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT yeqing thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT fuyang thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT weijian thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT zhangyong thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT lirongqing thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT wangzhiqiang longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT fengxudong longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT gechunlei longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT yangyi longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT liangna longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT yeqing longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT fuyang longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT weijian longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT zhangyong longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy AT lirongqing longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy |